Kerrisdale Advisers’s Charles River Laboratories CRL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $1.13M | Sell |
|
|||||
|
2025
Q1 | $1.51M | Buy |
|
|||||
|
2024
Q4 | $1.6M | Buy |
|
|||||
|
2024
Q3 | $1.28M | Sell |
|
|||||
|
2024
Q2 | $2.02M | Sell |
|
|||||
|
2024
Q1 | $2.98M | Sell |
|
|||||
|
2023
Q4 | $5.94M | Buy |
|
|||||
|
2023
Q3 | $4.21M | Buy |
|
|||||
|
2023
Q2 | $955K | Buy |
|
|||||
|
2022
Q3 | – | Sell |
|
|||||
|
2022
Q2 | $1.59M | Sell |
|
|||||
|
2022
Q1 | $3.97M | Sell |
|
|||||
|
2021
Q4 | $28M | Buy |
|
|||||
|
2021
Q3 | $14.2M | Sell |
|
|||||
|
2021
Q2 | $21.6M | Sell |
|
|||||
|
2021
Q1 | $35.7M | Sell |
|
|||||
|
2020
Q4 | $44.9M | Sell |
|
|||||
|
2020
Q3 | $50.7M | Sell |
|
|||||
|
2020
Q2 | $44M | Buy |
|
|||||
|
2020
Q1 | $31.5M | Buy |
|
|||||
|
2019
Q4 | $21.2M | Buy |
|